Jaktinib,hydroxyurea
suzhou zelgen
['mpnsm', '#mpn']
congress|#eha2023 yi zhang, zhejiang university school of medicine presents results from a double blind phase 3 study evaluating jaktinib vs hu in intermediate/high-risk mf. svr35 rates at week 24 were 72.3% for jaktinib vs. 17.4% for hu (p 0.0001) #mpn #mpnsm #medicalcongress 
Lifting levels of knowledge in myeloproliferative neoplasms (MPN). A global online platform providing latest treatment options and medical information #mpnsm